^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CHEK1 (Checkpoint kinase 1)

    i
    Apply
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (NCI-2017-02296) (NCT03375307)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/03/2020
    Primary completion :
    12/16/2025
    Completion :
    12/16/2025
    TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC
    |
    FANCG mutation
    |
    Lynparza (olaparib)
    Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) (NCT05700721)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/02/2023
    Primary completion :
    08/07/2025
    Completion :
    08/07/2027
    PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52
    |
    PD-L1 expression
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Pembrolizumab, Olaparib, and Temozolomide for People with Glioma (NCT05188508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/14/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM) (NCT05222971)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/01/2022
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1
    |
    ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers (MK3475-A53) (NCT05379972)
    Phase 2
    University of Colorado, Denver
    Recruiting
    Last update posted :
    11/26/2024
    Initiation :
    01/12/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2028
    HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4
    |
    HRD
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA (NCT05515575)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    11/05/2024
    Initiation :
    08/23/2022
    Primary completion :
    08/01/2026
    Completion :
    08/01/2026
    BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4
    |
    Zejula (niraparib)
    Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (NCT03047135)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    05/24/2023
    Completion :
    05/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Lynparza (olaparib)
    Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma (NCT03061188)
    Phase 1
    Northwestern University
    Completed
    Last update posted :
    06/12/2024
    Initiation :
    05/23/2017
    Primary completion :
    03/11/2018
    Completion :
    08/04/2020
    BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC
    |
    MSI-H/dMMR • RAD50 mutation
    |
    Opdivo (nivolumab) • veliparib (ABT-888)
    Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (NCT05038839)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    02/09/2022
    Primary completion :
    06/03/2024
    Completion :
    06/03/2024
    BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression
    |
    Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)
    A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer (BrUOG 360) (NCT04253262)
    Phase 1/2
    Brown University
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    04/03/2020
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRIP1 mutation
    |
    Rubraca (rucaparib) • Aliqopa (copanlisib)
    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774)
    Phase N/A
    Massive Bio, Inc.
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    01/01/2018
    Primary completion :
    12/01/2026
    Completion :
    06/01/2027
    EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703
    |
    HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
    Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    04/26/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation
    |
    Talzenna (talazoparib)
    Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) (NCT03786796)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/05/2024
    Initiation :
    06/03/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF) (NCT04053322)
    Phase 2
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/05/2024
    Initiation :
    08/26/2019
    Primary completion :
    11/15/2023
    Completion :
    08/01/2027
    HER-2 • ER • BRCA1 • BRCA2 • MSI • CDK12 • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • CHEK1 • BARD1 • NBN • RAD54L • FANCL • PPP2R2A
    |
    ER positive • BRCA1 mutation • HER-2 negative • FANCA deletion
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • fulvestrant
    Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects (NCT04030559)
    Phase 2
    Marc Dall'Era, MD
    Recruiting
    Last update posted :
    01/22/2024
    Initiation :
    02/25/2020
    Primary completion :
    08/01/2024
    Completion :
    02/01/2025
    BRCA1 • BRCA2 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • CHEK1 • NBN • FANCL • FANCD2 • GEN1
    |
    Zejula (niraparib)
    Niraparib and Dostarlimab in HRD Solid Tumors (DIDO) (NCT04983745)
    Phase 2
    West Cancer Center
    Recruiting
    Last update posted :
    12/21/2023
    Initiation :
    11/29/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI
    |
    BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations (NCT03448718)
    Phase 2
    Matthew Galsky
    Completed
    Last update posted :
    11/22/2023
    Initiation :
    04/17/2018
    Primary completion :
    07/14/2021
    Completion :
    10/15/2021
    BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3
    |
    Lynparza (olaparib)
    Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes (NCT04187833)
    Phase 2
    Case Comprehensive Cancer Center
    Completed
    Last update posted :
    11/16/2023
    Initiation :
    06/05/2020
    Primary completion :
    10/13/2023
    Completion :
    10/13/2023
    TMB • BRCA1 • BRCA2 • BAP1 • MLH1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • PARP1 • CHEK1 • NBN • HDAC2 • EMSY • ERCC3 • PRKDC • LIG3
    |
    Opdivo (nivolumab) • Talzenna (talazoparib)
    A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) (NCT03207347)
    Phase 2
    University of Florida
    Completed
    Last update posted :
    09/15/2023
    Initiation :
    08/13/2018
    Primary completion :
    08/30/2022
    Completion :
    08/30/2022
    PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4
    |
    BARD1 mutation
    |
    Zejula (niraparib)
    ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer (NCI-2022-03599) (NCT05368506)
    Phase 1
    OHSU Knight Cancer Institute
    Withdrawn
    Last update posted :
    05/04/2023
    Initiation :
    07/30/2023
    Primary completion :
    09/30/2024
    Completion :
    07/31/2025
    HER-2 • ER • PGR • CHEK1 • CDK1
    |
    azenosertib (ZN-c3)
    A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD) (NCT04985721)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Recruiting
    Last update posted :
    03/15/2023
    Initiation :
    02/24/2022
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib)
    The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation (PROact) (NCT05167175)
    Phase 2
    Hongqian Guo
    Recruiting
    Last update posted :
    10/25/2022
    Initiation :
    03/01/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer (NCT05461261)
    Phase 2
    The Affiliated Nanjing Drum Tower Hospital of N...
    Recruiting
    Last update posted :
    10/24/2022
    Initiation :
    07/01/2022
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • ATM • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    cisplatin • carboplatin • docetaxel
    To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA) (NCT02476968)
    Phase 4
    AstraZeneca
    Completed
    Last update posted :
    09/10/2022
    Initiation :
    09/28/2015
    Primary completion :
    04/17/2020
    Completion :
    12/17/2021
    BRCA1 • BRCA2 • CDK12 • BRCA • MUC16 • CHEK2 • RAD51B • BRIP1 • RAD51C • CHEK1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation
    |
    Lynparza (olaparib)
    Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency (NCT04892693)
    Phase 2
    Seoul National University Hospital
    Recruiting
    Last update posted :
    09/02/2022
    Initiation :
    05/25/2021
    Primary completion :
    05/10/2023
    Completion :
    05/10/2025
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Talzenna (talazoparib)
    Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE) (NCT04508803)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    06/30/2022
    Initiation :
    09/14/2020
    Primary completion :
    11/20/2022
    Completion :
    12/28/2022
    HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression
    |
    Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)
    Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma (NCT04895046)
    Phase 2
    Walid Shaib, MD
    Withdrawn
    Last update posted :
    06/29/2022
    Initiation :
    10/11/2021
    Primary completion :
    09/01/2022
    Completion :
    09/01/2023
    BRCA1 • BRCA2 • PTEN • ARID1A • BAP1 • CHEK2 • RAD51 • BRIP1 • CHEK1 • BARD1 • NBN • FANCM • EMSY • RPA1
    |
    HRD signature
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (PROspect) (NCT05262608)
    Phase 2
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Recruiting
    Last update posted :
    03/02/2022
    Initiation :
    12/07/2021
    Primary completion :
    02/26/2024
    Completion :
    04/26/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) (NCT05116579)
    Phase N/A
    Sun Yat-sen University
    Recruiting
    Last update posted :
    11/11/2021
    Initiation :
    10/31/2021
    Primary completion :
    03/31/2023
    Completion :
    08/31/2023
    BRCA1 • BRCA2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation • BRCA1 mutation + ATM mutation • CHEK1 expression
    Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS (NCT04592211)
    Phase 1/2
    Yonsei University
    Not yet recruiting
    Last update posted :
    08/31/2021
    Initiation :
    10/01/2021
    Primary completion :
    12/31/2022
    Completion :
    05/31/2023
    HER-2 • BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
    Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd (TAC-GReD) (NCT04740190)
    Phase 2
    The University of Hong Kong
    Recruiting
    Last update posted :
    08/20/2021
    Initiation :
    01/01/2021
    Primary completion :
    12/31/2022
    Completion :
    12/31/2023
    BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • FANCF • WRN • FANCD2 • FANCE • FANCC
    |
    PTEN mutation
    |
    carboplatin • Talzenna (talazoparib)
    Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) (NCT03377556)
    Phase 2
    Southwest Oncology Group
    Completed
    Last update posted :
    06/23/2021
    Initiation :
    03/03/2017
    Primary completion :
    01/10/2021
    Completion :
    04/16/2021
    BRCA1 • BRCA2 • HRD • PALB2 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCM • FANCD2 • RPA1 • FANCC
    |
    BARD1 mutation • RPA1 mutation
    |
    Talzenna (talazoparib)
    Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response (NCT04692662)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/12/2021
    Initiation :
    01/15/2021
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • CDK12 • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • FANCF mutation • FANCG mutation
    |
    Talzenna (talazoparib)
    Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy (CaNCaP03) (NCT02324998)
    Phase 1
    Cambridge University Hospitals NHS Foundation T...
    Completed
    Last update posted :
    08/29/2019
    Initiation :
    12/01/2016
    Primary completion :
    05/01/2019
    Completion :
    05/01/2019
    RAD51 • CHEK1 • FANCD2
    |
    Lynparza (olaparib) • Firmagon (degarelix)